Price controls under consideration by the administration would reduce the biopharmaceutical industry’s investment in R&D, which would slow the pace of drug discovery. It would also damage the life science innovation ecosystem because biopharma firms contribute to knowledge sharing, including through university research in all 50 states, scientific publications (over 12,500 in 2017 alone), and other activities designed to develop and disseminate discoveries.